Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc

Biotech R&D: Neurocrine vs. Alkermes Spending Trends

__timestampAlkermes plcNeurocrine Biosciences, Inc.
Wednesday, January 1, 2014775300046425000
Thursday, January 1, 2015401900081491000
Friday, January 1, 2016230100094291000
Sunday, January 1, 20177232000121827000
Monday, January 1, 201868895000160524000
Tuesday, January 1, 201952816000200000000
Wednesday, January 1, 20201946000275000000
Friday, January 1, 20211020000328100000
Saturday, January 1, 2022393842000463800000
Sunday, January 1, 2023270806000565000000
Monday, January 1, 2024245326000731100000
Loading chart...

Unlocking the unknown

Innovation Spending: A Tale of Two Biotechs

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Alkermes plc have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Neurocrine Biosciences increased its R&D expenses by over 1,100%, peaking in 2023 with a staggering 565% increase from its 2014 levels. In contrast, Alkermes plc's R&D spending showed more volatility, with a significant spike in 2022, reaching nearly 400% of its 2014 expenditure. This divergence highlights Neurocrine's consistent growth strategy, while Alkermes appears to adopt a more fluctuating approach. As the biotech industry continues to evolve, these spending patterns may offer insights into each company's future innovation trajectory and market positioning. Understanding these trends is crucial for investors and stakeholders aiming to gauge the potential of these biotech giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025